Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Deffered Revenue (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $12.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue rose 6.12% year-over-year to $12.6 million, compared with a TTM value of $12.6 million through Sep 2025, up 6.12%, and an annual FY2024 reading of $12.2 million, up 12.88% over the prior year.
  • Non-Current Deffered Revenue was $12.6 million for Q3 2025 at Spero Therapeutics, roughly flat from $12.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $23.8 million in Q3 2023 and bottomed at $8.8 million in Q4 2021.
  • Average Non-Current Deffered Revenue over 5 years is $13.5 million, with a median of $12.2 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue crashed 59.46% in 2024, then soared 39.1% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $8.8 million in 2021, then rose by 10.87% to $9.7 million in 2022, then increased by 11.13% to $10.8 million in 2023, then rose by 12.88% to $12.2 million in 2024, then grew by 2.91% to $12.6 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for SPRO at $12.6 million in Q3 2025, $12.6 million in Q2 2025, and $12.6 million in Q1 2025.